Rimiducid (AP1903)

DRUG4 trials

Sponsors

M.D. Anderson Cancer Center, Beijing Biotech

Conditions

B2 ThymomaColorectal CancerGastric Cancer, MetastaticHodgkin LymphomaLarge B-cell LymphomaMinimal Residual DiseaseThymic Carcinoma

Phase 1

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

RecruitingNCT06358430

M.D. Anderson Cancer CenterColorectal Cancer, Minimal Residual Disease

Start: 2024-12-02End: 2029-01-18Target: 42Updated: 2026-05-20

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

Not yet recruitingNCT07509008

M.D. Anderson Cancer CenterGastric Cancer, Metastatic

Start: 2026-09-01End: 2030-07-01Target: 10Updated: 2026-05-05

Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma

RecruitingNCT07598955

Beijing BiotechB2 Thymoma, Thymic Carcinoma

Start: 2026-03-02End: 2028-04-17Target: 36Updated: 2026-05-20

Phase 2

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Not yet recruitingNCT07164469

M.D. Anderson Cancer CenterHodgkin Lymphoma, Large B-cell Lymphoma

Start: 2026-06-28End: 2033-09-30Target: 100Updated: 2026-05-06

Related Papers

Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD).

Journal of Clinical Oncology2026-01-10